An Innovative Synbiotic Formulation Decreases Free Serum Indoxyl Sulfate, Small Intestine Permeability and Ameliorates Gastrointestinal Symptoms in a Randomized Pilot Trial in Stage IIIb-IV CKD Patients

An Innovative Synbiotic Formulation Decreases Free Serum Indoxyl Sulfate, Small Intestine Permeability and Ameliorates Gastrointestinal Symptoms in a Randomized Pilot Trial in Stage IIIb-IV CKD Patients

Proteolytic dysbiosis of the gut microbiota has been recognized as both a typical feature of chronic kidney disease (CKD) and a risk factor for its progression. Blood accumulation of gut-derived uremic toxins (UTs) like indoxyl sulfate (IS) and p-cresyl sulfate (PCS), intestinal permeability and con...

Full description

Bibliographic Details
Main Authors: Carmela Cosola, Maria Teresa Rocchetti, Ighli di Bari, Paola Maria Acquaviva, Valentina Maranzano, Simone Corciulo, Agostino Di Ciaula, Domenica Maria Di Palo, Flavia Maria La Forgia, Sergio Fontana, Maria De Angelis, Piero Portincasa, Loreto Gesualdo
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Toxins
Subjects:
chronic kidney disease
uremic toxins
intestinal permeability
indoxyl sulfate
randomized pilot trial
synbiotic
Online Access:https://www.mdpi.com/2072-6651/13/5/334

Internet

https://www.mdpi.com/2072-6651/13/5/334

Similar Items